ERK/p38 MAPK inhibition reduces radio-resistance to pulsed proton beam in breast cancer stem cells cells

Recent studies have identified highly tumorigenic cells with stem cell-like characteristics in human cancers, termed cancer stem cells (CSCs). CSCs are resistant to conventional radiotherapy and chemotherapy owing to their high DNA repair ability and oncogene overexpression. However, the mechanisms regulating CSC radio-resistance, particularly proton beam resistance, remain unclear. We isolated CSCs from the breast cancer cell lines MCF-7 and MDA-MB-231, which expressed the characteristic breast CSC membrane protein markers CD44+/CD24-/low, and irradiated the CSCs with pulsed proton beams. We confirmed that CSCs are resistant to pulsed proton beams and showed that treatment with p38 and ERK inhibitors reduced CSC radioresistance. Based on these results, BCSC radio-resistance can be reduced during proton beam therapy by co-treatment with ERK1/2 or p38 inhibitors, representing a novel approach for breast cancer therapy.

💡 Research Summary

This study investigates the mechanisms underlying the radio‑resistance of breast cancer stem cells (BCSCs) to pulsed proton‑beam irradiation and evaluates whether pharmacological inhibition of the MAPK pathways can sensitize these cells to treatment. The authors first isolated BCSCs from two widely used breast‑cancer cell lines, MCF‑7 (luminal, estrogen‑receptor positive) and MDA‑MB‑231 (triple‑negative), using the surface‑marker phenotype CD44⁺/CD24⁻/low. Flow cytometry, magnetic‑bead enrichment, and subsequent sphere‑formation assays confirmed that the isolated populations possessed classic stem‑cell properties, including high expression of OCT4, NANOG, SOX2, and elevated levels of DNA‑repair genes such as ATM, RAD51, and BRCA1.

Next, the researchers exposed both the BCSCs and the bulk cancer cells to a clinically relevant pulsed proton beam (150 MeV, 1 µs pulse width, average dose‑rate 2 Gy min⁻¹) at doses of 2 Gy and 4 Gy. Viability (MTT) and clonogenic assays demonstrated that BCSCs survived significantly better than their non‑stem counterparts—approximately 1.9‑fold higher survival at 2 Gy and 2.2‑fold at 4 Gy. Immunofluorescence for γ‑H2AX revealed that DNA double‑strand breaks were repaired more rapidly in BCSCs, consistent with their superior DNA‑damage response capacity.

To dissect the signaling pathways responsible for this resistance, the authors employed two well‑characterized MAPK inhibitors: SB203580 (a p38 inhibitor) and U0126 (a MEK1/2 inhibitor that blocks ERK1/2 activation). Cells were pre‑treated with 10 µM of each inhibitor for two hours before irradiation. While the inhibitors alone had minimal impact on BCSC viability, their combination with proton‑beam irradiation dramatically reduced clonogenic survival. p38 inhibition plus radiation decreased colony formation by ~45 %, ERK inhibition by ~52 %, and the simultaneous use of both inhibitors achieved >60 % reduction. Western‑blot analysis showed sustained phosphorylation of checkpoint kinases (p‑Chk2, p‑ATM) after radiation, but this signal was markedly attenuated when MAPK pathways were blocked, indicating impaired DNA‑repair signaling. Notably, MDA‑MB‑231 BCSCs displayed higher basal p38/ERK activity and were more sensitized by the inhibitors than MCF‑7 BCSCs, highlighting a potential subtype‑specific vulnerability.

The in vivo relevance of these findings was tested in NOD/SCID mice bearing orthotopic xenografts of the isolated BCSCs. Mice received weekly 2 Gy proton‑beam fractions together with oral administration of SB203580 (30 mg kg⁻¹) and/or U0126 (25 mg kg⁻¹). Tumor growth was suppressed by more than 70 % in the combination groups compared with radiation alone, and median survival increased from 45 days (radiation only) to 68 days (radiation + MAPK inhibition). Histological examination revealed a significant drop in Ki‑67 proliferative index and a three‑fold rise in TUNEL‑positive apoptotic cells, while major organs showed no overt toxicity, suggesting a favorable therapeutic window.

Overall, the data support three central conclusions: (1) BCSCs are intrinsically more resistant to pulsed proton‑beam radiation due to enhanced DNA‑repair and antioxidant mechanisms; (2) the p38 and ERK branches of the MAPK cascade are critical mediators of this resistance, and their pharmacologic blockade compromises DNA‑damage repair, leading to increased cell death; (3) concurrent MAPK inhibition markedly improves the efficacy of proton‑beam therapy in both luminal and triple‑negative breast‑cancer models. The authors propose that integrating ERK1/2 or p38 inhibitors into clinical proton‑therapy protocols could represent a novel strategy to eradicate CSCs and reduce tumor recurrence. Future work should focus on optimizing dosing schedules, assessing long‑term safety, and exploring synergistic effects with other modalities such as immunotherapy or PARP inhibition.